reports
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; August 12, 2025 – (Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,580 shares at DKK 1,025.00,1,874 shares at DKK 1,050.00, and109 shares at DKK 1,161.00. Proceeds to the company are approximately DKK 4.7 million....
Genmab Announces Financial Results for the First Half of 2025
Genmab Announces Financial Results for the First Half of 2025 August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R2 in patients with relapsed or refractory FLRinatabart sesutecan (Rina-S®) continues to progress, demonstrating encouraging antitumor activity in endometrial cancer in data presented at the 2025 ASCO Annual MeetingData from over 40 abstracts highlighting the depth, breadth and strength of Genmab’s comprehensive epcori...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary ...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Company Announcement COPENHAGEN, Denmark; August 7, 2025 Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.0001) and Progression-Free Survival (HR 0.21, p-value
Scancell Holdings: 1 director
A director at Scancell Holdings bought 9,400,000 shares at 10.0p and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Scancell: SCOPE’ing out iSCIB1+ in advanced melanoma
Data from SCOPE, examining Scancell’s highly promising ImmunoBody “off-the-shelf” DNA cancer vaccine, appear to show that a meaningful, additional benefit can be achieved when added to standard-of-care (SoC) CPIs as a first-line treatment in advanced melanoma. iSCIB1+ has been selected as the candidate for further development; it works in a larger, and easily identifiable, patient group that represents 80% of all advanced melanomas, double that of SCIB1. The benefits of iSCIB1+ will need to be d...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Trinity Delta LIghthouse: Scancell
Trinity Delta view: The positive latest results from the SCOPE study of Scancell’s “off the shelf” cancer vaccine SCIB1/iSCIB1+ are important for three reasons: (1) data consistently show a clinically meaningful and commercially relevant improvement over currently achievable outcomes; (2) the better efficacy can be achieved without worsening SoC safety and tolerability; and (3) the selection of iSCIB1+ should allow a larger group of patients (c 80% of melanoma patients vs c 40% with SCIB1) to be...
Scancell reports Phase 2 data showing strongly improved outcomes in La...
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type patients, representing 80% of total patients - greatly exceeding the 48-50% for standard of care 12-month progression-free survival also markedly improved, with a 20% increase over standard of care iSCIB1+ Immunobody® selected for future development; planning for registration...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quart...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025 Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,5...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Scancell: Key ImmunoBody clinical data imminent
Scancell’s investment case centres on the lead cancer vaccines from its highly promising ImmunoBody and Moditope “off the shelf” platforms. Key data from two programmes will determine future development plans and define the commercial opportunities. The first, and most important, are the imminent SCOPE trial results: a successful outcome will allow selection of the optimal candidate (SCIB1 or iSCIB1+) to take into a potentially pivotal Phase II/III trial. Later in 2025, early data from the renal...
Genmab Announces Changes to its Executive Committee
Genmab Announces Changes to its Executive Committee Media ReleaseCOPENHAGEN, Denmark; July 1, 2025 Birgitte Stephensen, Executive Vice President and Chief Legal Officer to retire after 23 years with Genmab A/SGreg Mueller joins as new Executive Vice President, General Counsel and Chief Legal Officer, effective July 1 (Nasdaq: GMAB) announced today that Birgitte Stephensen, Executive Vice President and Chief Legal Officer, will retire from Genmab after a successful tenure that spanned 23 years with the company. Greg Mueller joins Genmab A/S as Executive Vice President, General Counsel and...
Completion of Share Buy-back Program
Completion of Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program was expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 23, 2025, to June 26, 2025: Tradi...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Cancer vaccine data due soon; Glymab developments too
Trinity Delta view: Upcoming data for Scancell’s highly promising “off the shelf” cancer vaccines (SCIB1/iSCIB1+ and Modi-1) will be key to determine future development plans and better assess the commercial opportunities. First up will likely be SCOPE data, where the key outcome will be selection of the optimal candidate (SCIB1 or iSCIB1+) to take into a potentially pivotal Phase II/III trial. Prior SCIB1 data suggest a commercially relevant and clinically meaningful improvement can be achieved...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 16 to June 20, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulat...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; June 17, 2025 – (Nasdaq: GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 27,396 shares at DKK 1,025.00,2,790 shares at DKK 1,050.00, 150 shares at DKK 1,147.50,1,557 shares at DKK 1,161.00, and224 shares at DKK 1,334.50. P...
Transactions with shares and linked securities in Genmab A/S made by m...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; June 17, 2025 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to p...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 16, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 9 to June 13, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulate...
Genmab Announces Epcoritamab Investigational Combination Therapy Demon...
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) led to an overall response rate (ORR) of 87 percent and a complete response (CR) rate of 65 percent in patients with relapsed or refractory (R/R) ...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; June 12, 2025 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 3,320 restricted stock units and 3,636 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK...
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 10, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 2 to June 6, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated...
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demons...
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Media ReleaseCOPENHAGEN, Denmark; June 2, 2025 New data showed that rinatabart sesutecan (Rina-S®) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response (mDOR) was not reached after a median follow-up of 7.7 monthsContinued evaluation of single-agent Rina-S 100 mg/m2 in patients with advanced endom...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.